Chronic inhibition of circulating dipeptidyl peptidase IV by FE 999011 delays the occurrence of diabetes in male Zucker diabetic fatty rats

Diabetes

Volumn 51, Issue 5, 2002, Pages 1461-1469

  Sudre, Béatrice ^a   Broqua, Pierre ^a,b,d   White, Richard B ^a,d   Ashworth, Doreen ^b,d   Michael Evans, D ^b,d   Haigh, Robert ^b,d   Junien, Jean Louis ^b,e   Aubert, Michel L ^a,c  

^a UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

^b Ferring Research Institute   (United Kingdom)

^c Hopital des Enfants Hopitaux universitaires de Geneve   (Switzerland)

^d MLA   (Switzerland)

^e Ferring Research Institute

Author keywords

[No Author keywords available]

Indexed keywords

1 (2' AMINO 3',3' DIMETHYLBUTANOYL)PYRROLIDINE 2 CARBONITRILE; DIPEPTIDYL PEPTIDASE IV; FATTY ACID; FE 999011; GLUCAGON LIKE PEPTIDE 1 [7-36] AMIDE; SERINE PROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHRONOPHARMACOLOGY; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; DRUG POTENCY; ENZYME ACTIVITY; ENZYME INHIBITION; FATTY ACID BLOOD LEVEL; FLUID INTAKE; FOOD INTAKE; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; HORMONE RELEASE; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; RAT STRAIN;

EID: 0036312876     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.51.5.1461     Document Type: Article

References (46)

1. Dipeptidyl-peptidase IV (CD26): Role in the inactivation of regulatory peptides
2. Enhanced insulin secretion and improved glucose tolerance in mice lacking CD 26
3. The enteroinsular axis in dipeptidyl peptidase IV-negative rats
4. Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide
5. Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats
6. Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice
7. Both subcutaneous and intravenously administered glucagon-like peptide-1 are rapidly degraded from the amino-acid terminus in type-2 diabetic patients and in healthy subjects
8. Glucagon-like peptide-1 and glucose-dependent insulin releasing polypeptide plasma levels in response to nutrients
9. The insulinotropic action of gastric inhibitory polypeptide in the perfused isolated rat pancreas
10. Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1(7-37)
11. Glucagon-like peptide-1 improves the ability of the β-cell to sense and respond to glucose in subjects with impaired glucose tolerance
12. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV
13. Phenotypes of mouse diabetes and rat fatty due to mutations in the OB (leptin) receptor
14. The diabetic Zucker fatty rat
15. Evolution of β-cell dysfunction in the male zucker diabetic fatty rat
16. Zucker diabetic fatty rat as a model for non-insulin-dependent diabetes mellitus
17. Glucose-dependent action of glucagon-like peptide-1(7-37) in vivo during short- or long-term administration
18. The effect of glucose and glucagon-like peptide-1 stimulation on insulin release in the perfused pancreas in a non-insulin-dependent diabetes mellitus animal model
19. Glucose-lowering and insulin-sensitizing actions of exendin-4: Studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats and diabetic rhesus monkeys (Macaca mulatta)
20. GLP-1 tablet in type 2 diabetes in fasting and postprandial conditions
21. Effects of glucagon-like peptide-1 on islet function and insulin sensitivity in noninsulin-dependent diabetes mellitus
22. Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM
23. Normalization of fasting glycemia by intravenous GLP-1 ([7-36 amide] or [7-37]) in type 2 diabetic patients
24. Glucagonlike peptide-1 agonist stimulation of β-cell growth and differentiation
25. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats
26. 2-Cyanopyrrolidides as potent, stable inhibitors of dipeptidyl peptidase IV
27. Studies of the diabetic action of streptozotocin
28. Comparison of the effect of native glucagon-like peptide I and dipeptidyl peptidase IV-resistant analogues on insulin release from rat pancreatic islets
29. Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone gluco-incretin hormone glucagon-like peptide 1
30. Divergent tissue-specific and developmental expression of receptors for glucagon and glucagon-like peptide-1 in the mouse
31. Functional receptors for the insulinotropic hormone glucagon-like peptide-I(7-37) on a somatostatin secreting cell line
32. Insulinotropic glucagon-like peptide I receptor expression in glucagon-producing alpha-cells of the rat endocrine pancreas
33. High-level expression of the GLP-1 receptor results in receptor desensitization
34. Distribution of glucagon-like peptide-1 (GLP-1) and other preproglucagon derived peptides in the rat hypothalamus and brain stem
35. Central administration of glucagon-like peptide-1 activates neuroendocrine neurons in the rat
36. Lipotoxicity in the pathogenesis of obesity-dependent NIDDM
37. How obesity causes diabetes in Zucker diabetic fatty rats
38. Tissue triglycerides, insulin resistance, and insulin production: Implications for hyperinsulinemia of obesity
39. β-cell lipotoxicity in the pathogenesis of non-insulin-dependent diabetes mellitus of obese rats: Impairment in adipocyte-β-cell relationships
40. Role of apoptosis in failure of β-cell mass compensation for insulin resistance and β-cell defects in the male Zucker diabetic fatty rat
41. Fatty acid-induced β cell apoptosis: A link between obesity and diabetes
42. GLP-1 and GLP-1(7-36) amide: Influences on basal and stimulated insulin and glucagon secretion in the mouse
43. CD26: A surface protease involved in T-cell activation
44. Dipeptidyl-peptidase IV/CD26 on T-cells: Analysis of an alternative T-cell activation pathway
45. Proteolytic processing of neuropeptide Y and peptide YY by dipeptidylpeptidase IV
46. Dipeptidylpeptidase IV and trypsin-like enzymatic degradation of human growth hormone releasing hormone in plasma